Charlotte Seyon Marcus, MD

Gynecologic Oncology
Accepting new patients
Sees patients age 18 and up
Penn Gynecologic Oncology Bucks County
View 1 additional location
Make an appointmentCall 800-789-7366
Headshot of Charlotte Seyon Marcus, MD
Penn Medicine Provider

About me

  • Adjunct Assistant Professor of Obstetrics and Gynecology

My education and training

  • Medical School: New York University School of Medicine
  • Residency: NYU Langone/Bellevue Hospital Center
  • Residency: George Washington University Medical Center
  • Fellowship: National Cancer Institute

Spoken languages

English
English

Reviews

Average Rating

339 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
May 2026
i received all if the answers and the delivery was reachable
Anonymous
May 2026
she is very caring and also professional
Anonymous
April 2026
her compassion for her patients
Anonymous
April 2026
attentive to my needs.

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Princeton Medical Center: Has privileges to treat patients in the hospital.
Dr. Marcus is a Penn Medicine physician. In New Jersey, providers are affiliated with Penn Medicine through Clinical Health Care Associates of New Jersey or Princeton Healthcare Affiliated Physicians, PC.

Qualifications and experience

Treatments and Conditions

Research

Publications

Penick ER, Hamilton CA, Maxwell GL, Marcus CS Germ cell, stromal, and other ovarian tumors. , Clinical Gynecologic Oncology, 9th ed. Elsevier, 12:290-313: 2018

Braverman JA, Marcus C, Garg R Anti-NMDA-receptor encephalitis: A neuropsychiatric syndrome associated with ovarian teratoma. , Gynecol Oncol Rep, 14:1-3: 2015

Bateman NW, Jaworski E, Ao W, Wang G, Litzi T, Dubil E, Marcus C, Conrads KA, Teng PN, Hood BL, Phippen NT, Vasicek LA, McGuire WP, Paz K, Sidransky D, Hamilton CA, Maxwell GL, Darcy KM, Conrads TP Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients. , J Proteome Res, 14(4):1900-10: 2015

Marcus, CS, Conrads KA, Teng PN, Dubil EA, Maxwell GL, Hamilton CA, Conrads TP. Pharmacologic inhibition of polo-like kinase 1 enhances paclitaxel-based cell killing in taxol resistant ovarian cancer cells. Poster presentation. , 45th Annual Meeting on Women’s Cancer, Society of Gynecologic Oncology. : 2014

Marcus CS, Maxwell GL, Darcy KM, Hamilton CA, McGuire WP Current approaches and challenges in managing and monitoring treatment response in ovarian cancer. , J Cancer, 5(1):25-30: 2014

Dubil EA, Marcus CS, Teng PN, Hood BL, Conrads KA, Guisong W, Maxwell GL, Hamilton CA, Conrads TP. Inhibition of ATM Kinase Sensitizes Epithelial Ovarian Cancer to Paclitaxel. Oral presentation. District Annual Meeting , ACOG Armed Forces District Annual Meeting : 2013

Risinger JI, Allard J, Chandran U, Day R, Chandramouli GV, Miller C, Zahn C, Oliver J, Litzi T, Marcus C, Dubil E, Byrd K, Cassablanca Y, Becich M, Berchuck A, Darcy KM, Hamilton CA, Conrads TP, Maxwell GL Gene expression analysis of early stage endometrial cancers reveals unique transcripts associated with grade and histology but not depth of invasion. , Front Oncol, 3:139: 2013

Marcus CS, Lepor, H. The factors predicting positive surgical margins after open radical retropubic prostatectomy. Poster presentation. , American Urological Association Annual Meeting. : 2005